HIV cell therapy biotech Addimmune to go public via SPAC merger; WHO names new Covid-19 'variant of interest'
10 Aug 2023
AcquisitionCell TherapyGene TherapyImmunotherapy
Addimmune, a biotech that is working on a cell therapy for HIV, announced Wednesday that it plans to merge with 10X Capital Venture’s SPAC to become a public company. The biotech intends to trade under the ticker $HIV.
The merger values Addimmune at about $500 million. Addimmune spun out of American Gene Technologies in June, taking the experimental HIV therapy with it. Jeff Galvin, who is CEO of American Gene Technologies, is also CEO of Addimmune.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.